Compare SiTime Corporation (SITM) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SiTime Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? SiTime Corporation trades at $654.38 (market cap $19.99B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $128.16B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 6.4× SiTime Corporation's market cap, and Vertex Pharmaceuticals Incorporated is more actively traded (806,603 versus 339,821). Which is the better fit depends on your goals — on Pluang, investors hold SiTime Corporation for 18 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SITM | VRTX | |
|---|---|---|
Market Cap | $19.99B | $128.16B |
Volume | 339,821 | 806,603 |
Sector | Technology | Health |
52-Week High | $901.60 | $557.96 |
52-Week Low | $252.76 | $407.37 |
Typical Hold Time | 18 Days | 120 Days |
Enterprise Value | $19.39B | $122.29B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SiTime Corp (SITM) trades at $665.16, down 6.46% today but maintains strong analyst support with 100% buy ratings and a $751.43 consensus price target. The stock shows bullish technical signals with support at $659 and resistance at $678, while recent quarterly earnings consistently beat expectations. Revenue growth accelerated to 126.5% year-over-year in Q2 2026, driven by AI infrastructure demand and the Renesas acquisition, though current valuation metrics remain elevated with P/S at 37.99.
SITM presents significant growth potential as a precision timing specialist benefiting from AI data center expansion, with projected revenue growth and margin expansion. However, risks include high valuation multiples, insider selling activity, and dependence on sustained AI infrastructure spending. The stock's current pullback may offer entry opportunity given strong fundamental momentum and unanimous Wall Street optimism.
Vertex Pharmaceuticals (VRTX) trades at $503.25, showing modest daily gains of 0.16%. The stock faces bearish technical signals with mixed earnings performance, missing Q4 2025 and Q2 2026 EPS estimates but beating Q1 2026. Strong fundamentals include 86% gross margins and 35% net income margins, with revenue projected to grow from $12B to $12.6B in 2026. Recent positive Phase II data for kidney disease drug inaxaplin highlights pipeline progress.
Outlook remains positive with 84% analyst buy ratings and $573 consensus target offering 14% upside. Key risks include reliance on cystic fibrosis franchise and competitive pressures. Earnings consistency and pipeline execution are critical for sustained growth amid current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About SiTime Corporation
SiTime Corporation is a leading provider of MEMS-based silicon timing solutions used in various electronic applications. The company’s products, including oscillators, resonators, and clock ICs, are designed to replace traditional quartz-based timing devices, offering superior performance, reliability, and smaller size in harsh environments. SiTime's solutions are adopted across high-growth markets such as 5G, data centers, industrial IoT, and automotive, positioning the company as a key enabler for next-generation electronic systems.
Read more on SITM →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
